As you will have noticed while reading this, we have launched our new website. Follow the link below for a blog entry from our CEO.CEO blog >
Medivir is a drug discovery and development company focusing on transformative cancer drugs. Our research and development are based on our extensive expertise in protease inhibitor design and nucleoside/nucleotide science.Our research >
Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.Our projects >
Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects in various phases.Partnership >
Continued discussions with FDA on proposed remetinostat phase III design results in delay in planned start of studyRead more
Phase I/II study design of birinapant in combination with Keytruda® to be presented on June 4 at the ASCO Annual MeetingRead more
Additional remetinostat phase II data will be presented at the International Investigative Dermatology meeting on May 18 and 19Read more
Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.